Search General Info
Search Education
Search Partnering Companies

David Baker

Philadelphia, Pennsylvania, United States
David is a co-founder of Vallon and has over 25 years of executive, operational and commercial leadership experience in the biopharma industry. He has been directly involved with the commercialization of five different billion dollar medications, including Adderall XR® and Vyvanse®, the two most successful ADHD brands.

Previously, David was Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharma company that completed a reverse merger with Arcturus Therapeutics in 2017. He worked at Shire for 10 years as VP, Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse®, and VP, ADHD Marketing.

David also worked at Merck for 14 years in marketing, sales, market research, and business development. David's therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia.

David earned a BA in Economics and Computer Science from Duke University and an MBA from Duke's Fuqua School of Business.
Speaking In
[Available On-Demand]
Vallon Pharmaceuticals is an emerging pharmaceutical company focused on the development of new…